--- title: "Callan Family Office LLC Buys New Position in Vertex Pharmaceuticals Incorporated $VRTX" type: "News" locale: "en" url: "https://longbridge.com/en/news/296677120.md" description: "Callan Family Office LLC initiated a new position in Vertex Pharmaceuticals (VRTX) during Q2, purchasing 15,789 shares valued at approximately $7.84 million, per SEC filings. Other institutions like Shelter Mutual and Keating Financial also increased stakes. Analysts generally maintain 'Moderate Buy' ratings with an average price target of $563.50. Recently, VRTX reported Q2 EPS of $4.73, slightly missing estimates, while revenue beat expectations at $3.33 billion." datetime: "2026-08-22T08:24:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296677120.md) - [en](https://longbridge.com/en/news/296677120.md) - [zh-HK](https://longbridge.com/zh-HK/news/296677120.md) generator: "portal-rs" --- # Callan Family Office LLC Buys New Position in Vertex Pharmaceuticals Incorporated $VRTX Callan Family Office LLC bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,789 shares of the pharmaceutical company's stock, valued at approximately $7,843,000. Get **Vertex Pharmaceuticals** alerts: - Vertex’s Crinetics Deal Balances Growth with Integration Risk Other hedge funds and other institutional investors also recently made changes to their positions in the company. Shelter Mutual Insurance Co acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $13,710,000. Keating Financial Advisory Services Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $278,000. Green Alpha Advisors LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at $274,000. OneAscent Family Office LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at $270,000. Finally, OneAscent Financial Services LLC acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $211,000. 90.96% of the stock is currently owned by institutional investors. ## Wall Street Analyst Weigh In A number of research firms have recently commented on VRTX. UBS Group boosted their price objective on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Truist Financial lifted their target price on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, July 29th. TD Cowen boosted their price target on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, June 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $563.50. - CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows **Get Our Latest Stock Report on VRTX** ## Vertex Pharmaceuticals Stock Performance NASDAQ VRTX opened at $548.05 on Friday. The stock has a market capitalization of $139.10 billion, a P/E ratio of 31.90, a P/E/G ratio of 2.24 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1 year low of $374.17 and a 1 year high of $555.32. The business's fifty day moving average is $492.65 and its two-hundred day moving average is $465.92. - How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts' consensus estimates of $4.74 by ($0.01). The company had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company posted $4.52 EPS. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.86 earnings per share for the current year. ## Insider Transactions at Vertex Pharmaceuticals In other news, CMO Carmen Bozic sold 596 shares of the company's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $482.50, for a total transaction of $287,570.00. Following the completion of the sale, the chief marketing officer directly owned 15,337 shares of the company's stock, valued at $7,400,102.50. This represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares of the company's stock, valued at $23,793,071.79. This trade represents a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 10,464 shares of company stock valued at $4,959,397 over the last three months. Company insiders own 0.20% of the company's stock. ## Vertex Pharmaceuticals Profile (Free Report) Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets. Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms. ## See Also - Five stocks we like better than Vertex Pharmaceuticals - Blueprint for a Boom: SEC Clears the Crypto Runway - Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss - Advance Auto Parts Plunged, But Its Turnaround Is Still Working - Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? **Want to see what other hedge funds are holding VRTX?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Vertex Pharmaceuticals Right Now? Before you consider Vertex Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list. While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) - [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md) - [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md) ## Related News & Research - [TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/296021261.md) - [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md) - [Are Wall Street Analysts Bullish on Vertex Stock?](https://longbridge.com/en/news/296449653.md) - [$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295956299.md) - [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**